Microcap Ledger Edesa Biotech, Inc. $EDSA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Toronto
- Fiscal year end
- September 30
- Shares outstanding
- 9,641,031 [10-Q 2026-08-13]
What the company doesAI summary of filing
Edesa Biotech is a clinical-stage biopharmaceutical company developing drug candidates for inflammatory and immune-related diseases. The company does not currently generate revenue from product sales. It acquires and develops drug candidates based on mechanisms of action that have demonstrated proof-of-concept in human subjects, focusing on medical dermatology and respiratory indications. The company makes money through potential milestone payments and royalties from licensing partners, and has received over C$37 million in competitive government grants and funding awards, including C$23 million in partially repayable funding from the Canadian government for EB05 development. [10-K 2025-12-12]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 9 months to Jun 2026 | — | −$11.87M | −$7.19M | $10.30M | [10-Q 2026-08-13] |
| FY ended Sep 2025 | — | −$7.19M | −$7.32M | $10.80M | [10-K 2025-12-12] |
| FY ended Sep 2024 | — | −$6.17M | −$4.89M | $1.00M | [10-K 2025-12-12] |
- Quarterly cash burn
- −$2.40M
- Cash runway Estimate
- ~12.9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-12-11 | 3,467,658 | [10-K/A 2024-12-20] |
| 2025-02-14 | 6,936,404 | [10-Q 2025-02-14] |
| 2025-05-14 | 7,022,678 | [10-Q 2025-05-14] |
| 2025-08-08 | 7,037,648 | [10-Q 2025-08-08] |
| 2025-12-12 | 8,333,823 | [10-K 2025-12-12] |
| 2026-02-12 | 8,348,161 | [10-Q 2026-02-13] |
| 2026-05-13 | 8,891,951 | [10-Q 2026-05-14] |
| 2026-08-13 | 9,641,031 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2026-07-02; declared effective 2026-07-13 [S-3 2026-07-02]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-05 | Nijhawan Pardeep | grant | 6,893 | — | [4 2026-10-06] |
| 2026-09-01 | Nijhawan Pardeep | grant | 5,714 | — | [4 2026-09-01] |
| 2026-08-03 | Nijhawan Pardeep | grant | 5,324 | — | [4 2026-08-04] |
| 2026-07-02 | Nijhawan Pardeep | grant | 3,378 | — | [4 2026-07-02] |
| 2026-06-16 | Nijhawan Pardeep | grant | 153,550 | $5.21 | [4 2026-06-16] |
| 2026-06-01 | Nijhawan Pardeep | grant | 1,671 | — | [4 2026-06-01] |
| 2026-05-27 | Marshall Patrick | grant | 19,000 | — | [4 2026-05-29] |
| 2026-05-27 | Macdonald Sean Arthur | grant | 19,000 | — | [4 2026-05-29] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-26 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-25 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-25 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-20 | 8-K | Material agreement entered; Other events |
| 2026-08-20 | 424B5 | Prospectus or prospectus supplement |
| 2026-08-19 | 424B5 | Prospectus or prospectus supplement |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations |
| 2026-07-13 | 424B3 | Prospectus or prospectus supplement |
| 2026-07-02 | S-3 | Registration statement |
| 2026-06-18 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-16 | 13D/A | Beneficial ownership report (5%+ holder) |
Alerts for $EDSA
Email me when Edesa Biotech, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.